Keep in mind that most CVOT top-line data announcements reveal very little information other than simply stating that the trial met or did not meet the primary endpoint. With the exception of Amarin's recent REDUCE-IT trial, which included %RRR and stats on the primary endpoint, the usual CVOT top-line doesn't have much detail. See this past post for examples of top-line announcements. 

Assuming that full data isn't presented and published until American Heart Association meeting in November, we could be 4.5 month away from knowing the juicy full BETonMACE results details. How much info that gets revealed at top-line could determine how much price movement there is before full data reveal. Questions of %RRR, CKD and cognition sub-studies and safety profile that may or may not be revealed at top-line could play a factor in price movement and valuation.

Whether BP would be made privy to some or all of the full data in advance for the purpose of negotiations under a non-disclosure agreement is a big unknown. Whether Resverlogix would be willing at all to show their cards before official full data release is also a big unknown.

BearDownAZ